新诺威帕妥珠单抗注射液上市申请获得受理

Core Viewpoint - New Horizon announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the marketing application of Pertuzumab injection, targeting HER2-positive breast cancer [1]. Group 1 - The marketing application for Pertuzumab injection has been accepted, indicating progress in the drug's approval process [1]. - Pertuzumab injection is a recombinant humanized anti-HER2 monoclonal antibody that specifically binds to the extracellular dimerization domain II of HER2, blocking the dimerization of HER2 with itself or other HER family members [1]. - The mechanism of action involves blocking the cell cycle and inducing apoptosis, which is crucial for treating HER2-positive breast cancer [1].